Table 1.
Baseline Characteristics and Demographics in Patients who Received Mold-Active Triazole Prophylaxis at Index/Enrollment (Full Analysis Set)
| Isavuconazole (n = 256) | Posaconazole (n = 397) | Voriconazole (n = 272) | Multiple/Sequenced MATsa (n = 252) | Total (N = 1177) | |
|---|---|---|---|---|---|
| Male, No. (%) | 139 (54.3) | 219 (55.2) | 160 (58.8) | 144 (57.1) | 662 (56.2) |
| Age, y | |||||
| Mean ± SD | 58.0 (14.92) | 56.5 (15.66) | 52.5 (19.07) | 57.0 (14.48) | 56.0 (16.23) |
| Min | 17 | 4 | <1 | 4 | <1 |
| Median | 62.0 | 60.0 | 57.5 | 61.0 | 60.0 |
| Max | 92 | 97 | 86 | 80 | 97 |
| Age ≥18 y, No. (%) | 255 (99.6) | 392 (98.7) | 260 (95.6) | 248 (98.4) | 1155 (98.1) |
| Race, No. (%) | |||||
| White | 212 (82.8) | 335 (84.4) | 215 (79.0) | 204 (81.0) | 966 (82.1) |
| Black/African American | 21 (8.2) | 29 (7.3) | 28 (10.3) | 20 (7.9) | 98 (8.3) |
| Asian | 7 (2.7) | 8 (2.0) | 5 (1.8) | 7 (2.8) | 27 (2.3) |
| American Indian/Alaskan Native | 1 (0.4) | 1 (0.3) | 2 (0.7) | 1 (0.4) | 5 (0.4) |
| Native Hawaiian or other Pacific Islander | 0 | 1 (0.3) | 1 (0.4) | 0 | 2 (0.2) |
| Other | 15 (5.9) | 23 (5.8) | 21 (7.7) | 20 (7.9) | 79 (6.7) |
| Hispanic ethnicity, No. (%) | 15 (5.9) | 23 (5.8) | 17 (6.3) | 15 (6.0) | 70 (6.0) |
| Underlying disease, No. (%) | |||||
| Hematological malignancy | 159 (62.1) | 357 (89.9) | 182 (66.9) | 202 (80.2) | 900 (76.5) |
| Receiving corticosteroids | 179 (69.9) | 222 (55.9) | 157 (57.7) | 150 (59.5) | 708 (60.2) |
| Neutropenia | 124 (48.4) | 305 (76.8) | 121 (44.5) | 156 (61.9) | 706 (60.0) |
| Receiving T-cell immunosuppressants | 115 (44.9) | 154 (38.8) | 129 (47.4) | 124 (49.2) | 522 (44.4) |
| HCT | 99 (38.7) | 131 (33.0) | 60 (22.1) | 103 (40.9) | 393 (33.4) |
| ICU | 69 (27.0) | 49 (12.3) | 73 (26.8) | 49 (19.4) | 240 (20.4) |
| Surgical (nontransplant) | 55 (21.5) | 68 (17.1) | 35 (12.9) | 32 (12.7) | 190 (16.1) |
| Solid organ transplant | 64 (25.0) | 11 (2.8) | 65 (23.9) | 32 (12.7) | 172 (14.6) |
| Solid tumor | 21 (8.2) | 34 (8.6) | 17 (6.3) | 17 (6.7) | 89 (7.6) |
| Trauma | 13 (5.1) | 9 (2.3) | 3 (1.1) | 2 (0.8) | 27 (2.3) |
| Iron overload | 5 (2.0) | 5 (1.3) | 6 (2.2) | 3 (1.2) | 19 (1.6) |
| Inherited immunodeficiency disorder | 3 (1.2) | 0 | 2 (0.7) | 3 (1.2) | 8 (0.7) |
| HIV/AIDS | 0 | 1 (0.3) | 2 (0.7) | 0 | 3 (0.3) |
| ≥1 previous MAT antifungal, No. (%)b | 137 (53.5) | 199 (50.1) | 81 (29.8) | 91 (36.1) | 508 (43.2) |
| ≥1 previous non-MAT antifungal, No. (%)c | 123 (48.0) | 190 (47.9) | 117 (43.0) | 139 (55.2) | 569 (48.3) |
Abbreviations: HCT, hematopoietic cell transplantation; HIV, human immunodeficiency virus; ICU, intensive care unit; max, maximum; min, minimum; MAT, mold-active triazole; SD, standard deviation.
a
Multiple/sequenced MATs describes patients receiving >1 MAT for prophylaxis throughout the study since index/enrollment.
b
Safety analysis set population; antifungal therapy taken (but not necessarily started) 90 days before MAT initiation at index/enrollment.
c
Any antifungal other than isavuconazole, posaconazole, or voriconazole.